The Royal Marsden NHS Foundation Trust
The Royal Marsden NHS Foundation Trust is a world-leading specialist cancer hospital. The Institute of Cancer Research works in close partnership with The Royal Marsden to take the results of our research rapidly into the clinic, with the aim of developing better treatments for cancer patients.
With hospitals in Chelsea and Sutton, and a chemotherapy suite at Kingston Hospital, The Royal Marsden treats 50,000 patients from across the UK and abroad every year. Many of these patients benefit from tailored treatment programmes accomplished through provision of molecular diagnostics – allowing doctors to determine which specific treatments will be of most benefit to a particular patient.
The ICR and The Royal Marsden are internationally renowned for our work together to conduct early- and late-phase clinical trials. Our joint Drug Development Unit, which sees around 300 patients per year, is one of the largest centres for phase I trials in the world and makes an important contribution to the worldwide effort to discover and develop new cancer drugs.
The ICR and The Royal Marsden together are ranked in the top four centres for cancer research and treatment worldwide. In 2006, we were selected as a National Institute for Health and Care Research Biomedical Research Centre specialising in cancer.
Kate Wilson was diagnosed with advanced ovarian cancer at the age of 43 and discovered she was carrying a BRCA gene mutation. She was prescribed a targeted drug called olaparib and five years on the cancer is stable. Here she explains why, thanks to new treatments, advanced cancer patients like her are navigating a new landscape, one where the language we use has yet to catch up.